146例老年心脑血管病血液流变学指标分析

目的研究老年心脑血管病患者的血液流变学改变、方法 对１４６例心脑血管病患者进行血液流变学检测，并设３７例健康者作为对照。结果血液流变学指标在高血压、冠心病、脑血管病和高脂血症中明显升高，与对照组比较有显著差异。高血压病的发病率为老年心脑血管病之首，其血液流变学指标有多项极显著升高。结论老年心脑血管病血液流变学指标有明显改变，其中以高血压病改变最为突出。     

老年冠心病患者血液流变学对比观察

本文就164例老年冠心病(CHD)患者血液流变学变化与100名健康老年人比较,发现老年CHD患者血液流变学改变是明显的,尤以全血低切粘度(?)20S~(-1)最为显著(t检验,P<0.002).从临床分型看,CHD越严重,血液流变学改变越明显.但隐匿型CHD患者与健康老年人的血液流变学指标比较,无明显差异.提示血液流变学检查不适用于CHD的早期诊断,但可以判断CHD的严重程度及其预后,对指导治疗及疗效观察有一定的参考价值.     

心脑血管病105例血液流变学分析

本文对105例心脑血管病(高血压、冠心病、脑血栓形成、心肌梗塞)进行了血液流变学检查,测定了全血比粘度、红细胞压积、血沉、血浆比粘度、红细胞电泳、血小板电泳与纤维蛋白原七项指标,结果显示:冠心病与高血压患者全血比粘度均值明显高于正常人,血浆比粘度以冠心病组增高最明显,红细胞压积以高血压组     

血液流变学检测与中医舌诊的相关性研究

本文从血液流变学检测方法对中医“舌诊”的理论进行了研究.通过150例冠心病、中风患者的血液流变检测、结合“舌象”的变化规律,发现血液流变学检测指标异常改变与中医“舌象”的变化存在着密切的联系,提示血液流变学检测指标可为中医“舌诊”的诊治提供某些规范的量化指标.     

舒血宁注射液对老年冠心病患者超敏C反应蛋白及血液流变学指标的影响

目的:观察舒血宁注射液对老年冠心病患者超敏C反应蛋白(hs-CRP)及血液流变学指标的影响。方法:将60例老年冠心病患者随机分为两组,治疗组:给予常规治疗并加用舒血宁注射液治疗;对照组:给予常规治疗。4周后观察两组治疗前后hs-CRP及血液流变学指标的变化。结果:两组治疗后血清hs-CRP明显降低,血液流变学指标中红细胞变形指数较治疗前升高,其它指标较治疗前降低,治疗组变化较对照组更为显著,有统计学差异(P<0.05)。结论:舒血宁注射液可显著降低老年冠心病患者血清hs-CRP及血液流变学指标水平,显著改善临床症状。     

Ⅱ型糖尿病和室间隔缺损合并脑血栓患者治疗前后血液流变学指标的检测分析

目的：探讨Ⅱ型糖尿病、室间隔缺损合并脑血栓患者血液流变学各项指标的改变情况,以及血液的宏观、微观流变特性的改变与各种疾病之间的关系,研究不同治疗方案对疾病血液流变学指标的影响。方法：采用血液流变学检测仪检测Ⅱ型糖尿病、室间隔缺损合并脑血栓患者血液流变学指标的变化,并与健康对照组、治疗后组进行比较,观察疾病发生及治疗过程对血液流变学指标的影响。结果：经过治疗后,Ⅱ型糖尿病、室间隔缺损合并脑血栓患者的血液黏度降低,血液流变学各项指标,包括全血高切粘度、全血低切粘度、血浆粘度、红细胞压积等均得到改善。结论：Ⅱ型糖尿病、室间隔缺损合并脑血栓患者的血液流变学指标均有不同程度的异常改变,是导致出现微循环障碍及多种合并症的重要原因。血液粘度的增高、红细胞变形性的恶化,都提示我们在体内肯定存在着诱发病灶,促使我们结合其他检查方法进一步确定疾病的诱因,改善异常的血液粘度学指标有助于临床疾病的治疗。     

高血压病、冠心病及高血脂症患者血液粘度变化及血浆粘度与血脂的关系

高血压、冠心病与高血脂症都直接危害人民的健康,高血压病还是发生中风最重要的危险因素之一。如何提高治愈率,减少中风的发生,已成为当务之急。基于此点,本文对以上三病种463例患者的血液流变学及血脂的测定结果进行了分析。结果表明:其血液流变学多项指标增高,与对照组相比有极显著性差异。三个病种的血脂也明显增高,含脂质高的血浆粘度也明显增高。提示临床在治疗上宜采用去脂,活血,降粘等综合治疗措施,预防与减少心肌梗塞与缺血性中风的发生。     

低分子肝素治疗不稳定型心绞痛的临床疗效及血液流变学改变

目的探讨低分子肝素对不稳定型心绞痛的疗效及血液流变学改变。方法根据WHO标准诊断为不稳定型心绞痛 (UAP)的患者78例 ,分为治疗组38例 ,对照组40例 ,治疗组给予低分子肝素加常规抗心绞痛治疗 ,对照组仅给予常规抗心绞痛治疗。比较两组的疗效 ,血液流变学改变、纤维蛋白原、血小板、出凝血时间等。结果治疗组有效率为82 % ,对照组为52 % (P<0.01)。对照组2例发生心肌梗塞 ,治疗组无一例发生心肌梗塞 ,治疗组血液流变学有明显改善。结论低分子肝素能明显改善心肌缺血 ,改善血液流变学 ,治疗UAP疗效确切     

杏丁改善冠心病患者甲襞微循环和血液流变性的作用观察

目的:观察杏丁改善冠心病(CHD)患者血液流变性的作用。方法:选择65例经冠状动脉造影诊断为CHD的患者,用杏丁注射液静脉滴注,治疗2周,分别于用药前后观察甲襞微循环、血液流变学等指标。结果:用药后甲襞微循环、血液流变学等相关指标明显改善。结论:杏丁注射液能改善冠心病患者的微循环及血液流变性。     

急性脑出血与急性脑梗塞患者血液流变学改变及其临床意义

观察36例脑出血及38例脑梗塞患者血液流变学的改变与50名正常人对照,结果两组患者的10项血液流变学指标均明显高于对照组(P相似文献   

Modern approach towards surgical treatment of coronary heart disease in diabetic patients

In the recent years there has been registered an increase in diabetes mellitus (DM) morbidity, especially among able-bodied citizens. The steady increase in amount of DM patients inevitably leads to the increase in the amount of diabetic CHD patients--candidates for the surgical myocardial revascularization. This article contains analysis of choice of myocardial revascularization technique in patients with CHD and concomitant DM. It also contains data from the study of endovascular and surgical treatment of CHD results in diabetic patients. This study also included postoperative complications analysis with exposure of complication development predictors and was held in Bakulev Scientific Centre of cardiovascular surgery. Results obtained in the study testify to the fact that DB increases relative risk of cardio-vascular complications (cardiac death, myocardial infarction and restenosis of special-purposed stenosis) development in patients with CHD after percutaneous coronary intervention with stenting. DM is an independent risk factor that increases myocardial infarction development risk, recurrence of stenocardia and shunt failure during the three year follow up after the coronary artery bypass grafting done in CHD patients.     

溶栓后PCI与pPCI治疗急性ST段抬高型心肌梗死的 临床效果研究

目的 研究溶栓后PCI和pPCI两种技术治疗急性ST段抬高型心肌梗死的临床效果。方法 选择我院收治的急性ST段抬高型心肌梗死患者86例,随机分为对照组和治疗组,每组43例。对照组采用pPCI方式治疗,治疗组采用溶栓后PCI方式治疗。观察两组患者的治疗有效率、不良反应、心功能指标（LVEF、LVEDd）、心肌梗死症状消失时间、心功能指标恢复正常时间、临床治疗总时间等临床指标。结果 治疗组治疗总有效率为90.70%,优于对照组的72.09%,差异具有统计学意义（P＜0.05）。治疗组不良反应发生1例,少于对照组的7例,差异具有统计学意义（P＜0.05）。治疗前后LVEF、LVEDd的改善幅度大于对照组,心肌梗死症状消失时间、心功能指标恢复正常时间、临床治疗总时间均短于对照组,差异具有统计学意义（P＜0.05）。结论 溶栓后经皮冠状动脉介入技术治疗急性ST段抬高型心肌梗死,能够提高治疗效果,改善心功能,缩短恢复时间,减少不良反应。     

茶色素治疗糖尿病前后血液流变性和微循环检测分析

目的：观察茶色素治疗糖尿病前后血液流变微循环的变化。方法：糖尿病人88例，男71例，女17例，年龄32～64岁。口服茶色素2粒（250mg），每日3次，疗程为30天。结果：血液流变学参数、微循环积分值、血生化指标、RIA都有明显改善（P＜0．01或P＜0．05）。结论：茶色素可以明显改善糖尿病人血液流变性和微循环多项检测指标，值得临床推广应用。     

七氟醚对老年冠心病患者非心脏手术血流动力学及心肌缺血事件的影响

 目的 探讨七氟醚对老年冠心病患者非心脏手术心肌保护作用。方法 选取4家医院择期行非心脏手术的老年冠心病患者165例,随机分两组：七氟醚持续吸入维持全身麻醉（S组,）和丙泊酚持续静脉输注维持全身麻醉（P组）。记录术中不同时点血压、心率,检测术前、术后即刻、术后第1天、第2天12导联心电图ST段和T波改变。术后随访30d,记录术后不稳定心绞痛、心梗、心衰及心源性死亡发生情况。结果 心电图提示的心肌缺血发生率：S组患者在术后各时点均低于P组,其中术后第1天(16.9% VS 30.5%)和第2天(16.9% VS 30.5%)的差异显著（p<0.05）。结论 七氟醚对老年冠心病患者接受非心脏手术具有一定的心肌保护作用,但并不改变患者心脏事件发生率。     

Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? The SAVE Investigators.

BACKGROUND. Medical practice patterns change in response to a variety of stimuli, one of which may be the publication of the results of randomized clinical trials. We assessed the temporal association between the publication of clinical trials on myocardial infarction and changes in treatment practices for this disorder. METHODS. We analyzed the use of aspirin before and after myocardial infarction and that of calcium antagonists after myocardial infarction in 2231 survivors of myocardial infarction enrolled in the Survival and Ventricular Enlargement (SAVE) study over a three-year period (from January 1987 through January 1990). The proportion of patients using these treatments was analyzed before and after the publication dates of three clinical trials: the Physicians' Health Study, published in January 1988, which supported the use of aspirin to prevent a first myocardial infarction; the Second International Study of Infarct Survival (ISIS-2), published in August 1988, which supported the use of aspirin after myocardial infarction; and the Multicenter Diltiazem Postinfarction Trial, published in August 1988, which reported a deleterious effect of diltiazem in some patients after myocardial infarction. RESULTS. The use of aspirin before myocardial infarction increased from 16.2 percent to 23.9 percent between January 1987 and January 1990 (P less than 0.001). Enrollment in the study after the publication of the Physicians' Health Study independently predicted aspirin use before myocardial infarction (odds ratio, 1.43; 95 percent confidence interval, 1.11 to 1.85). The use of aspirin after myocardial infarction increased from 38.8 percent to 71.9 percent (P less than 0.001) during the three-year study period. Enrollment in the study after the publication of ISIS-2 independently predicted the use of aspirin after myocardial infarction (odds ratio, 2.28; 95 percent confidence interval, 1.89 to 2.76). The use of calcium antagonists after myocardial infarction decreased from 57.1 percent to 33.1 percent (P less than 0.001) during the study period. Enrollment in the study after the publication of the Multicenter Diltiazem Postinfarction Trial independently predicted the use of calcium antagonists after myocardial infarction (odds ratio, 0.47; 95 percent confidence interval, 0.39 to 0.57). CONCLUSIONS. These observations suggest that randomized clinical trials have a measurable influence on medical practice patterns.     

Myocardial reperfusion in thrombolysis A 99Tcm-Sestamibi SPECT study in patients with acute myocardial infarction.

This study presents the outcome of myocardial scintigraphy performed before and after thrombolytic treatment in 16 patients with acute myocardial infarction using 99Tcm-Sestamibi (Cardiolite, Du Pont Scandinavia AB, Kista, Sweden). The patients were given 99Tcm-Sestamibi intravenously as soon as possible after the decision to give thrombolytic treatment. When the patients were in a clinically stable state after the thrombolytic treatment, myocardial perfusion was analysed with the gamma camera using single photon emission computerized tomography (SPECT). A second 99Tcm-Sestamibi tomography was carried out on the second to fourth day after the myocardial infarction. Data reconstruction was done with the 'Bull's eye technique'. Nine patients received thrombolysis < 3 h from the onset of pain. In this group six patients (66%) improved their myocardial perfusion by > 10% after treatment, while all seven patients who received treatment > or = 3 h after the onset of pain improved their myocardial perfusion by < 10%. This study emphasises the importance of early diagnosis and treatment of patients with acute myocardial infarction in order to salvage myocardium.     

通心络对AMI患者再灌注后心肌和微血管的保护性研究

目的 研究通心络对急性心肌梗死患者再灌注后心肌和微血管的保护性。方法 选取2018年1月~2019年1月在我院治疗的成功实施PCI或溶栓治疗的急性心肌梗死患者94例,随机分为对照组和观察组,各47例。对照组采用常规药物治疗,观察组在对照组基础上联合通心络治疗,对比两组治疗后1周、2周、1个月室壁异常节段恢复率、左室舒张末容积（LVEDV）、左室射血分数（LVEF）、丙二醛（MDA）、一氧化氮（NO）等指标。结果 观察组治疗后1周、2周、1个月异常室壁运动节段恢复率均高于对照组（P＜0.05）;治疗后两组LVEF、LVEDV均较治疗前有改善,且观察组优于对照组（P＜0.05）;治疗后两组MDA均较治疗前降低,NO水平均较治疗前升高,且观察组优于对照组（P＜0.05）。结论 通心络对急性心肌梗死患者再灌注后心肌和微血管具有良好的保护性,可减轻对患者心肌缺损再灌注损伤。     

综合性心理治疗冠心病的临床研究

目的　观察综合性心理治疗冠心病的疗效。方法　将 1 0 0例冠心病患者按心理检查时单双序号分为研究组和对照组。研究组在常规药物治疗的基础上 ,采用行为干预治疗、生物反馈、放松训练、音乐疗法、支持性心理治疗等综合疗法。对照组仅常规药物治疗。每位患者均于治疗前、治疗后 3个月和 6个月检测临床指标 :血压 ( SBP、DBP)、血脂 ( TC、TG、HDL-C)进行治疗前及同期组间比较 ;治疗后 6个月观察心电图 ST-T和临床疗效 ;并行治疗前和治疗后 6个月给两组患者测查生活质量评定问卷 ( GQOL-74 ) ,进行治疗前后及同期组间比较。结果　研究组治疗后 3个月和 6个月临床指标改善明显优于对照组 ( P<0 .0 5 ) ,治疗 6个月后研究组的心电图 ST-T改善和临床疗效及生活质量得分明显高于对照组。结论　综合性心理疗法能有效提高冠心病患者的临床治疗效果和生活质量。     

Type A behavior and mortality from coronary heart disease

The relation of behavior (Type A or Type B) to the morbidity and mortality of coronary heart disease (CHD) is still debated. We studied the survival of 257 male patients with CHD from the initial, 8.5-year phase of the Western Collaborative Group Study to see whether behavior type--as assessed by a structured interview before the CHD event--was related to subsequent CHD mortality. Behavior type was not related to mortality in 26 patients who died within 24 hours of the coronary event. However, of the 231 patients who survived for 24 hours, the mortality rate associated with CHD among 160 Type A patients studied during an average 12.7 years was 19.1 per 1000 person-years. This was unexpectedly lower than the corresponding rate of 31.7 among 71 Type B patients who were followed for an average of 11.5 years (P = 0.04). In a proportional-hazards survival analysis, which controlled for variable follow-up time, the type of initial coronary event, and traditional risk variables, the relative CHD-associated mortality rate among Type A as compared with Type B patients was 0.58 (P = 0.03; 95 percent confidence interval, 0.35 to 0.96). The lower mortality among Type A subjects occurred in both younger and older subgroups but was more pronounced in patients whose initial diagnosis was symptomatic myocardial infarction rather than silent myocardial infarction or angina pectoris. This apparent advantage associated with Type A behavior is surprising and needs confirmation, but the results do indicate that patients with CHD and a Type A behavior pattern are not at increased risk for subsequent CHD mortality.     

活血康脉丸对冠心病患者甲襞微循环的影响

应用活血康脉丸对80例冠心病患者进行治疗.以甲疑微循环各有关项目数据作为主要指标进行临床观察.结果发现甲壁微循环的血液流态、管修形态、穆周状态、总积分值均有明显改善.治疗前与治疗后相比,差异非常显著(P相似文献